Advanced BioMedical Technologies Inc. (ABMT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.46: the stock has moved about 46% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAdvanced BioMedical Technologies Inc. (ABMT) trades at $0.0005. Advanced Biomedical Technologies, Inc. is a development stage company specializing in biomaterial internal fixation devices for orthopedic trauma, sports medicine, cartilage repair, and reconstructive dental procedures. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for ABMT: ABMT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Advanced BioMedical Technologies Inc. (ABMT) Healthcare & Pipeline Overview
Advanced Biomedical Technologies, Inc. is a New York-based development stage company focused on designing, manufacturing, and marketing biomaterial internal fixation devices. Specializing in polymer osteosynthesis devices, it addresses orthopedic trauma, sports-related injuries, cartilage repair, and reconstructive dental procedures, positioning itself within the specialized medical device sector.
What Is the Investment Thesis for ABMT?
Advanced Biomedical Technologies, Inc. (ABMT) operates as a development stage company, presenting a unique investment profile characterized by its focus on biomaterial internal fixation devices for critical medical applications. The company's high gross margin of 81.9% suggests strong potential profitability once its products achieve broader market adoption and scale, indicating efficient cost management in its core production processes. However, as a development stage entity, ABMT currently exhibits a significant negative profit margin of -190.2%, reflecting substantial ongoing R&D and operational expenses typical before commercialization reaches critical mass. The company's beta of 1.46 indicates higher volatility compared to the broader market, which is common for smaller, development-stage healthcare firms. Key value drivers include the successful advancement of its polymer osteosynthesis devices through clinical validation and regulatory approvals, leading to increased market penetration in orthopedic trauma, sports medicine, cartilage repair, and reconstructive dental procedures. Growth catalysts would involve securing strategic partnerships for distribution, expanding product lines to address a wider range of indications, and achieving commercial milestones that transition the company from development to sustained revenue generation. The inherent risks include the lengthy and capital-intensive nature of medical device development, regulatory hurdles, and intense competition within the medical device industry.
Based on FMP financials and quantitative analysis
ABMT Key Highlights
Operates as a development stage company, focusing on biomaterial internal fixation devices.
- Maintains a high Gross Margin of 81.9%, indicating strong product-level profitability potential.
- Reports a Profit Margin of -190.2%, reflecting significant investment in development and operations.
- Exhibits a Beta of 1.46, suggesting higher stock price volatility relative to the overall market.
- Employs a team of 17 individuals, indicating a lean operational structure for a specialized medical device developer.
Who Are ABMT's Competitors?
ABMT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.76 | -9.01% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.01 | -1.11% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.74 | -1.09% | $31.4M | — |
| SNWV SANUWAVE Health, Inc. | $4.70 | -2.49% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.92 | -2.01% | $48.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.89 | +4.29% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.67 | -1.19% | $81.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.60 | +1.96% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABMT's Key Strengths?
Specialized focus on biomaterial internal fixation devices for niche medical applications.
- High gross margin of 81.9% indicates strong potential profitability at scale.
- Dedicated team of 17 employees allows for focused R&D and operational efficiency.
- Addresses critical needs in orthopedic trauma, sports medicine, cartilage repair, and reconstructive dentistry.
What Are ABMT's Weaknesses?
Currently a development stage company, implying limited revenue generation.
- Significant negative profit margin of -190.2% due to high development costs.
- Small employee base of 17 may limit rapid scaling or broad market penetration.
- Reliance on successful product development and regulatory approvals for commercial viability.
What Are the Key Risks for ABMT?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- As a development stage company, ABMT faces significant financial risk due to its negative profit margin of -190.2%, indicating substantial operating losses.
- The lengthy and capital-intensive nature of medical device development and regulatory approval processes could deplete financial resources.
- Intense competition from established players in the medical device market could hinder market penetration and adoption of ABMT's products.
- Regulatory hurdles and potential delays in obtaining necessary clearances for its biomaterial devices pose a significant risk to commercialization.
- The 'OTC Other' listing tier and 'Unknown' disclosure status present risks related to transparency, liquidity, and investor confidence.
What Threats Does ABMT Face?
- Intense competition from established medical device manufacturers with larger resources.
- Stringent and evolving regulatory landscape for medical devices, particularly for novel biomaterials.
- Risk of product obsolescence due to rapid technological advancements in the healthcare sector.
- Capital intensity of R&D and manufacturing, requiring significant ongoing investment.
- Market acceptance challenges for new biomaterial technologies compared to traditional fixation methods.
What Are ABMT's Competitive Advantages?
- Proprietary biomaterial technology and designs for polymer osteosynthesis devices.
- Specialized focus on niche applications like cartilage repair and specific reconstructive dental procedures.
- Potential for intellectual property protection (patents) on device designs and manufacturing processes.
- Expertise in the development and application of advanced polymer-based medical implants.
- Early mover advantage or specialized knowledge in specific biomaterial internal fixation segments.
What Does ABMT Do?
Advanced Biomedical Technologies, Inc. (ABMT), founded in 2002 and headquartered in New York City, is a development stage company operating within the specialized medical devices segment of the healthcare sector. Initially incorporated as Geostar Mineral Corporation, the company underwent a strategic transformation and rebranded to Advanced Biomedical Technologies, Inc. in March 2009, signaling a definitive pivot towards the biomedical field. ABMT's core business revolves around the design, development, manufacturing, and marketing of advanced biomaterial internal fixation devices. These innovative products are crucial for stabilizing and repairing tissues and bones within the human body. The company's product portfolio primarily features polymer osteosynthesis devices, which include a range of surgical screws, binding wires, rods, and other related medical instruments. These devices are engineered to cater to several critical medical applications, including the treatment of orthopedic trauma, which encompasses injuries to bones, joints, and ligaments. Furthermore, ABMT's offerings extend to sports-related medical treatments, addressing the unique needs of athletes and active individuals recovering from injuries. The company also focuses on solutions for cartilage repair, a complex area requiring specialized biomaterials to facilitate regeneration and structural integrity. Beyond musculoskeletal applications, Advanced Biomedical Technologies, Inc. contributes to reconstructive dental procedures, providing devices that aid in the structural restoration and stabilization required in oral and maxillofacial surgery. With a dedicated team of 17 employees, ABMT is committed to advancing biomaterial technology to meet unmet clinical needs in these specialized medical fields.
What Products and Services Does ABMT Offer?
- Designs and develops biomaterial internal fixation devices for medical applications.
- Manufactures polymer osteosynthesis devices, including surgical screws, binding wires, and rods.
- Markets these specialized medical devices to healthcare providers.
- Provides solutions for treating orthopedic trauma, such as bone fractures and joint injuries.
- Offers devices for sports-related medical treatments, aiding in athletic injury recovery.
- Develops products specifically for cartilage repair procedures.
- Supplies devices used in reconstructive dental procedures for oral and maxillofacial stabilization.
- Focuses on advanced biomaterials to create innovative internal fixation solutions.
How Does ABMT Make Money?
- Research, develop, and obtain regulatory approvals for novel biomaterial internal fixation devices.
- Manufacture specialized polymer osteosynthesis devices in-house or through contract manufacturers.
- Market and sell these proprietary medical devices directly to hospitals, clinics, and surgical centers.
- Generate revenue from the sales of surgical screws, binding wires, rods, and related medical devices.
What Industry Does ABMT Operate In?
Advanced Biomedical Technologies, Inc. operates within the highly specialized and innovation-driven Medical - Devices industry, a critical segment of the broader Healthcare sector. This industry is characterized by continuous technological advancements, stringent regulatory oversight, and a growing global demand driven by an aging population, increasing prevalence of chronic diseases, and advancements in surgical techniques. ABMT's focus on biomaterial internal fixation devices places it within a niche market segment addressing orthopedic trauma, sports medicine, cartilage repair, and reconstructive dentistry. The market for orthopedic devices alone is substantial, with global projections often reaching hundreds of billions of dollars, driven by factors like sports injuries, road accidents, and degenerative conditions. The competitive landscape is fragmented, featuring large multinational corporations with extensive product portfolios and distribution networks, alongside numerous smaller, specialized companies like ABMT focusing on niche technologies or specific clinical needs. ABMT's differentiation lies in its biomaterial polymer osteosynthesis devices, aiming to offer potentially superior or novel solutions for internal fixation, positioning it as an innovator in this specialized field.
Who Are ABMT's Key Customers?
- Orthopedic surgeons and orthopedic departments in hospitals.
- Sports medicine clinics and specialists treating athletic injuries.
- Oral and maxillofacial surgeons and dental clinics performing reconstructive procedures.
- Hospitals and surgical centers requiring internal fixation devices for various trauma and reconstructive surgeries.
- Cartilage repair specialists and research institutions focused on regenerative medicine.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Advanced BioMedical Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Hui Wang. ABMT has traded publicly since 2008.
Key Financial Metrics
Return on equity for Advanced BioMedical Technologies Inc. stands at 6.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Advanced BioMedical Technologies Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
11 transactions · 0 purchases, 0 sales, 11 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
ABMT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ABMT Latest News
No recent news available for ABMT.
ABMT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ABMT.
Price Targets
Wall Street price target analysis for ABMT.
ABMT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ABMT; grades run from A+ (80-100) to F (below 30).
Leadership: Hui Wang
CEO
As CEO of Advanced Biomedical Technologies, Inc., a development stage company, the role typically involves overseeing strategic direction, product development, fundraising, and navigating the complex regulatory landscape inherent in the medical device industry.
Track Record: Under Hui Wang's leadership, Advanced Biomedical Technologies, Inc. has maintained its focus as a development stage company specializing in biomaterial internal fixation devices. Wang manages a team of 17 employees, steering the company's efforts in designing, developing, and manufacturing polymer osteosynthesis devices for orthopedic trauma, sports medicine, cartilage repair, and reconstructive dental procedures. Key achievements and strategic decisions under their tenure are not explicitly detailed in the provided information.
ABMT OTC Market Information
Advanced Biomedical Technologies, Inc. (ABMT) trades on the 'OTC Other' tier, which represents the lowest and most speculative segment of the OTC market. Unlike companies listed on national exchanges like the NYSE or NASDAQ, which adhere to strict listing requirements regarding financial reporting, corporate governance, and minimum share prices, 'OTC Other' companies face minimal to no disclosure requirements. This tier is typically reserved for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group, making it challenging for investors to access comprehensive and current data.
- OTC Tier: OTC Other
- Lack of transparent and timely financial disclosure, making fundamental analysis challenging.
- Extremely low trading volume and liquidity, leading to wide bid-ask spreads and difficulty in trading.
- Increased susceptibility to fraud and manipulation due to minimal regulatory oversight.
- Significant price volatility and potential for rapid, unpredictable price movements.
- Limited access to capital markets for fundraising, hindering growth and development.
- Verify the company's current operational status and any recent business developments.
- Seek out any available financial statements or disclosures, even if unofficial or limited.
- Research management's background and track record beyond publicly available information.
- Assess the viability and market potential of their biomaterial devices independently.
- Investigate any legal or regulatory actions against the company or its management.
- Understand the current share structure, outstanding shares, and any dilution risks.
- Evaluate the company's ability to secure funding for its development stage operations.
- Has a stated physical headquarters in New York, New York.
- Identifies a specific CEO, Hui Wang, leading the company.
- Clearly defined business model focused on designing and manufacturing medical devices.
- Founded in 2002, indicating a long operational history, albeit with a name change.
- Operates in a tangible and specialized sector (Medical - Devices).
Common Questions About ABMT (Healthcare)
What are the main risks for ABMT?
Advanced Biomedical Technologies, Inc. faces several significant risks, primarily stemming from its status as a development stage company. Financially, a substantial negative profit margin of -190.2% indicates ongoing losses and a high burn rate.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited public financial data available due to 'development stage' status and 'OTC Other' tier.
- Specific details on CEO's background and track record are not publicly available and thus marked as 'Unknown' or 'Not provided'.